Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 84

1.

Outcome of paraosseous extra-medullary disease in newly diagnosed multiple myeloma patients treated with new drugs.

Montefusco V, Gay F, Spada S, De Paoli L, Di Raimondo F, Ribolla R, Musolino C, Patriarca F, Musto P, Galieni P, Ballanti S, Nozzoli C, Cascavilla N, Ben-Yehuda D, Nagler A, Hajek R, Offidani M, Liberati AM, Sonneveld P, Cavo M, Corradini P, Boccadoro M.

Haematologica. 2019 Jun 20. pii: haematol.2019.219139. doi: 10.3324/haematol.2019.219139. [Epub ahead of print]

2.

Once-weekly versus twice-weekly carfilzomib in patients with newly diagnosed multiple myeloma: a pooled analysis of two phase I/II studies.

Bringhen S, Mina R, Petrucci MT, Gaidano G, Ballanti S, Musto P, Offidani M, Spada S, Benevolo G, Ponticelli E, Galieni P, Cavo M, Di Toritto TC, Di Raimondo F, Montefusco V, Palumbo A, Boccadoro M, Larocca A.

Haematologica. 2019 Aug;104(8):1640-1647. doi: 10.3324/haematol.2018.208272. Epub 2019 Feb 7.

3.

Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM study.

Cuneo A, Follows G, Rigolin GM, Piciocchi A, Tedeschi A, Trentin L, Perez AM, Coscia M, Laurenti L, Musuraca G, Farina L, Delgado AR, Orlandi EM, Galieni P, Mauro FR, Visco C, Amendola A, Billio A, Marasca R, Chiarenza A, Meneghini V, Ilariucci F, Marchetti M, Molica S, Re F, Gaidano G, Gonzalez M, Forconi F, Ciolli S, Cortelezzi A, Montillo M, Smolej L, Schuh A, Eyre TA, Kennedy B, Bowles KM, Vignetti M, de la Serna J, Moreno C, Foà R, Ghia P; GIMEMA, European Research Initiative on CLL (ERIC) and UK CLL forum.

Haematologica. 2018 Jul;103(7):1209-1217. doi: 10.3324/haematol.2018.189837. Epub 2018 Apr 19.

4.

Phase 1/2 study of weekly carfilzomib, cyclophosphamide, dexamethasone in newly diagnosed transplant-ineligible myeloma.

Bringhen S, D'Agostino M, De Paoli L, Montefusco V, Liberati AM, Galieni P, Grammatico S, Muccio VE, Esma F, De Angelis C, Musto P, Ballanti S, Offidani M, Petrucci MT, Gaidano G, Corradini P, Palumbo A, Sonneveld P, Boccadoro M.

Leukemia. 2018 Apr;32(4):979-985. doi: 10.1038/leu.2017.327. Epub 2017 Nov 16.

PMID:
29263440
5.

Array CGH analysis reveals deletion of chromosome 22q11 in CLL with normal karyotype and no fish alterations.

Mestichelli F, Dalsass A, Ferretti S, Camaioni E, Angelini M, Mei S, Pezzoni V, Travaglini F, Troiani E, Angelini S, Galieni P.

Br J Haematol. 2018 Oct;183(1):152-155. doi: 10.1111/bjh.14949. Epub 2017 Oct 8. No abstract available.

PMID:
28990183
6.

Modified BEAM as conditioning regimen for lymphoma patients undergoing autologous hematopoietic stem cell transplantation.

Galieni P, Troiani E, Bigazzi C, Mazzotta S, Ruggieri M, Pezzoni V, Dalsass A, Mestichelli F, Caraffa P, Travaglini F, Ferretti S, Angelini M, Angelini S, Falcioni S.

Bone Marrow Transplant. 2018 Jan;53(1):91-93. doi: 10.1038/bmt.2017.206. Epub 2017 Oct 2. No abstract available.

PMID:
28967898
7.

Chlorambucil plus rituximab as front-line therapy for elderly and/or unfit chronic lymphocytic leukemia patients: correlation with biologically-based risk stratification.

Laurenti L, Innocenti I, Autore F, Ciolli S, Mauro FR, Mannina D, Del Poeta G, D'Arena G, Massaia M, Coscia M, Molica S, Pozzato G, Efremov DG, Vannata B, Marasca R, Galieni P, Cuneo A, Orlando S, Piciocchi A, Boncompagni R, Vincelli D, Liberati AM, Russo F, Foá R.

Haematologica. 2017 Sep;102(9):e352-e355. doi: 10.3324/haematol.2016.156901. Epub 2017 Jun 8. No abstract available.

8.

Assessment of the interlaboratory variability and robustness of JAK2V617F mutation assays: A study involving a consortium of 19 Italian laboratories.

Perricone M, Palandri F, Ottaviani E, Angelini M, Bagli L, Bellesia E, Donati M, Gemmati D, Zucchini P, Mancini S, Marchica V, Trubini S, De Matteis G, Di Zacomo S, Favarato M, Fioroni A, Bolzonella C, Maccari G, Navaglia F, Gatti D, Toffolatti L, Orlandi L, Laloux V, Manfrini M, Galieni P, Giannini B, Tieghi A, Barulli S, Serino ML, Maccaferri M, Scortechini AR, Giuliani N, Vallisa D, Bonifacio M, Accorsi P, Salbe C, Fazio V, Gusella M, Toffoletti E, Salvucci M, Svaldi M, Gherlinzoni F, Cassavia F, Orsini F, Martinelli G.

Oncotarget. 2017 May 16;8(20):32608-32617. doi: 10.18632/oncotarget.15940.

9.

Factors predicting survival in chronic lymphocytic leukemia patients developing Richter syndrome transformation into Hodgkin lymphoma.

Mauro FR, Galieni P, Tedeschi A, Laurenti L, Del Poeta G, Reda G, Motta M, Gozzetti A, Murru R, Caputo MD, Campanelli M, Frustaci AM, Innocenti I, Raponi S, Guarini A, Morabito F, Foà R, Gentile M.

Am J Hematol. 2017 Jun;92(6):529-535. doi: 10.1002/ajh.24714. Epub 2017 Apr 18.

10.

Management of anaemia in oncohaematological patients treated with biosimilar epoetin alfa: results of an Italian observational, retrospective study.

Rosti G, Petrini M, Bosi A, Galieni P, Bernardi D, Giglio G, Dorotea L, Falini B, Scelzi E, Veltri E, Castelli R, Longagnani C, Raggi T, Simonetti F.

Ther Adv Med Oncol. 2017 Jan;9(1):22-32. doi: 10.1177/1758834016670554. Epub 2016 Oct 22.

11.

Circulating plasma cells in newly diagnosed symptomatic multiple myeloma as a possible prognostic marker for patients with standard-risk cytogenetics.

Vagnoni D, Travaglini F, Pezzoni V, Ruggieri M, Bigazzi C, Dalsass A, Mestichelli F, Troiani E, Falcioni S, Mazzotta S, Natale A, Angelini M, Ferretti S, Angelini S, Galieni P.

Br J Haematol. 2015 Aug;170(4):523-31. doi: 10.1111/bjh.13484. Epub 2015 May 26.

PMID:
26010293
12.

Bendamustine, etoposide, cytarabine, melphalan, and autologous stem cell rescue produce a 72% 3-year PFS in resistant lymphoma.

Visani G, Stefani PM, Capria S, Malerba L, Galieni P, Gaudio F, Specchia G, Meloni G, Gherlinzoni F, Gonella R, Gobbi M, Santoro A, Ferrara F, Rocchi M, Ocio EM, Caballero MD, Loscocco F, Isidori A.

Blood. 2014 Nov 6;124(19):3029-31. doi: 10.1182/blood-2014-08-596668. No abstract available.

13.

Correlation between eight-gene expression profiling and response to therapy of newly diagnosed multiple myeloma patients treated with thalidomide-dexamethasone incorporated into double autologous transplantation.

Terragna C, Renzulli M, Remondini D, Tagliafico E, Di Raimondo F, Patriarca F, Martinelli G, Roncaglia E, Masini L, Tosi P, Zamagni E, Tacchetti P, Ledda A, Brioli A, Angelucci E, Testoni N, Marzocchi G, Galieni P, Gozzetti A, Martello M, Dico F, Mancuso K, Cavo M.

Ann Hematol. 2013 Sep;92(9):1271-80. doi: 10.1007/s00277-013-1757-6. Epub 2013 May 10.

PMID:
23660628
14.

6q deletion detected by fluorescence in situ hybridization using bacterial artificial chromosome in chronic lymphocytic leukemia.

Dalsass A, Mestichelli F, Ruggieri M, Gaspari P, Pezzoni V, Vagnoni D, Angelini M, Angelini S, Bigazzi C, Falcioni S, Troiani E, Alesiani F, Catarini M, Attolico I, Scortechini I, Discepoli G, Galieni P.

Eur J Haematol. 2013 Jul;91(1):10-9. doi: 10.1111/ejh.12115. Epub 2013 May 24.

PMID:
23560441
15.

Assessment of vulnerability measures and their effect on survival in a real-life population of multiple myeloma patients registered at Marche Region Multiple Myeloma Registry.

Offidani M, Corvatta L, Polloni C, Centurioni R, Visani G, Brunori M, Gentili S, Catarini M, Samori A, Blasi N, Alesiani F, Caraffa P, Burattini M, Galieni P, Fraticelli P, Ferranti M, Giuliodori L, Leoni P.

Clin Lymphoma Myeloma Leuk. 2012 Dec;12(6):423-32. doi: 10.1016/j.clml.2012.06.008. Epub 2012 Sep 14.

PMID:
22981966
16.

Chromosome aberrations detected by conventional karyotyping using novel mitogens in chronic lymphocytic leukemia with "normal" FISH: correlations with clinicobiologic parameters.

Rigolin GM, Cibien F, Martinelli S, Formigaro L, Rizzotto L, Tammiso E, Saccenti E, Bardi A, Cavazzini F, Ciccone M, Nichele I, Pizzolo G, Zaja F, Fanin R, Galieni P, Dalsass A, Mestichelli F, Testa N, Negrini M, Cuneo A.

Blood. 2012 Mar 8;119(10):2310-3. doi: 10.1182/blood-2011-11-395269. Epub 2012 Jan 13.

17.

BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant/relapsed lymphoma patients.

Visani G, Malerba L, Stefani PM, Capria S, Galieni P, Gaudio F, Specchia G, Meloni G, Gherlinzoni F, Giardini C, Falcioni S, Cuberli F, Gobbi M, Sarina B, Santoro A, Ferrara F, Rocchi M, Ocio EM, Caballero MD, Isidori A.

Blood. 2011 Sep 22;118(12):3419-25. doi: 10.1182/blood-2011-04-351924. Epub 2011 Aug 3.

18.

Infectious complications in patients with multiple myeloma treated with new drug combinations containing thalidomide.

Offidani M, Corvatta L, Polloni C, Gentili S, Brioni A, Visani G, Galieni P, Brunori M, Alesiani F, Catarini M, Centurioni R, Samori A, Blasi N, Ferranti M, Fraticelli P, Mele A, Rizzi R, Larocca F, Leoni P.

Leuk Lymphoma. 2011 May;52(5):776-85. doi: 10.3109/10428194.2011.555027. Epub 2011 Feb 21.

PMID:
21338282
19.

Primary plasma cell leukemia: a retrospective multicenter study of 73 patients.

Pagano L, Valentini CG, De Stefano V, Venditti A, Visani G, Petrucci MT, Candoni A, Specchia G, Visco C, Pogliani EM, Ferrara F, Galieni P, Gozzetti A, Fianchi L, De Muro M, Leone G, Musto P, Pulsoni A; GIMEMA-ALWP (Gruppo Italiano Malattie EMatologiche dell'Adulto, Acute Leukemia Working Party: coordinator Sergio Amadori).

Ann Oncol. 2011 Jul;22(7):1628-35. doi: 10.1093/annonc/mdq646. Epub 2011 Jan 20.

PMID:
21252060
20.

Melphalan, prednisone, and thalidomide versus thalidomide, dexamethasone, and pegylated liposomal doxorubicin regimen in very elderly patients with multiple myeloma: a case-match study.

Offidani M, Leoni P, Bringhen S, Corvatta L, Larocca A, Gentili S, Oliva S, Polloni C, Galieni P, Catarini M, Alesiani F, Mele A, Brunori M, Blasi N, Ferranti M, Visani G, Boccadoro M, Palumbo A.

Leuk Lymphoma. 2010 Aug;51(8):1444-9. doi: 10.3109/10428194.2010.486878.

PMID:
20496998
21.

ThaDD plus high dose therapy and autologous stem cell transplantation does not appear superior to ThaDD plus maintenance in elderly patients with de novo multiple myeloma.

Offidani M, Leoni P, Corvatta L, Polloni C, Gentili S, Savini A, Alesiani F, Brunori M, Catarini M, Visani G, Samori A, Burattini M, Centurioni R, Montanari M, Fraticelli P, Ruggieri M, Falcioni S, Galieni P.

Eur J Haematol. 2010 Jun;84(6):474-83. doi: 10.1111/j.1600-0609.2010.01418.x. Epub 2010 Mar 11.

PMID:
20331733
22.

High versus standard dose methylprednisolone in the acute phase of idiopathic thrombotic thrombocytopenic purpura: a randomized study.

Balduini CL, Gugliotta L, Luppi M, Laurenti L, Klersy C, Pieresca C, Quintini G, Iuliano F, Re R, Spedini P, Vianelli N, Zaccaria A, Pogliani EM, Musso R, Bobbio Pallavicini E, Quarta G, Galieni P, Fragasso A, Casella G, Noris P, Ascari E; Italian TTP Study Group.

Ann Hematol. 2010 Jun;89(6):591-6. doi: 10.1007/s00277-009-0877-5. Epub 2009 Dec 23.

PMID:
20033409
23.

BU/melphalan and auto-SCT in AML patients in first CR: a 'Gruppo Italiano Trapianto di Midollo Osseo (GITMO)' retrospective study.

Lemoli RM, D'Addio A, Marotta G, Pezzullo L, Zuffa E, Montanari M, De Vivo A, Bonini A, Galieni P, Carella AM, Guidi S, Michieli M, Olivieri A, Bosi A.

Bone Marrow Transplant. 2010 Apr;45(4):640-6. doi: 10.1038/bmt.2009.235. Epub 2009 Oct 5.

PMID:
19802019
24.

Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: a phase 2 trial of the GIMEMA CML Working Party.

Castagnetti F, Palandri F, Amabile M, Testoni N, Luatti S, Soverini S, Iacobucci I, Breccia M, Rege Cambrin G, Stagno F, Specchia G, Galieni P, Iuliano F, Pane F, Saglio G, Alimena G, Martinelli G, Baccarani M, Rosti G; GIMEMA CML Working Party.

Blood. 2009 Apr 9;113(15):3428-34. doi: 10.1182/blood-2007-08-103499. Epub 2009 Feb 11.

25.

Thalidomide-dexamethasone versus interferon-alpha-dexamethasone as maintenance treatment after ThaDD induction for multiple myeloma: a prospective, multicentre, randomised study.

Offidani M, Corvatta L, Polloni C, Piersantelli MN, Gentili S, Galieni P, Visani G, Alesiani F, Catarini M, Brunori M, Samori A, Burattini M, Centurioni R, Ferranti M, Giuliodori L, Candela M, Mele A, Marconi M, Leoni P.

Br J Haematol. 2009 Mar;144(5):653-9. doi: 10.1111/j.1365-2141.2008.07495.x. Epub 2008 Nov 13.

PMID:
19036082
26.

Serum C-reactive protein at diagnosis and response to therapy is the most powerful factor predicting outcome of multiple myeloma treated with thalidomide/ anthracycline-based therapy.

Offidani M, Corvatta L, Polloni C, Piersantelli MN, Galieni P, Visani G, Alesiani F, Catarini M, Brunori M, Burattini M, Centurioni R, Ferranti M, Giuliodori L, Candela M, Mele A, Marconi M, Leoni P.

Clin Lymphoma Myeloma. 2008 Oct;8(5):294-9. doi: 10.3816/CLM.2008.n.041.

PMID:
18854284
27.

Time-Dependent Kinetics of Tretinoin in Chronic Myelogenous Leukaemia during Intermittent Dose Scheduling: 1 Week On/1 Week Off.

Regazzi MB, Russo D, Iacona I, Sacchi S, Visani G, Lazzarino M, Avvisati G, Pelicci PG, Dastoli G, Grandi C, Spreafico S, Grattoni R, Galieni P, Rupoli S, Maiolo AM, Guerra E, Liberati AM.

Clin Drug Investig. 1998;16(1):25-33.

PMID:
18370515
28.

Thalidomide, dexamethasone, and pegylated liposomal doxorubicin (ThaDD) for patients older than 65 years with newly diagnosed multiple myeloma.

Offidani M, Corvatta L, Piersantelli MN, Visani G, Alesiani F, Brunori M, Galieni P, Catarini M, Burattini M, Centurioni R, Ferranti M, Rupoli S, Scortechini AR, Giuliodori L, Candela M, Capelli D, Montanari M, Olivieri A, Poloni A, Polloni C, Marconi M, Leoni P.

Blood. 2006 Oct 1;108(7):2159-64. Epub 2006 Jun 8.

29.

Low-dose thalidomide with pegylated liposomal doxorubicin and high-dose dexamethasone for relapsed/refractory multiple myeloma: a prospective, multicenter, phase II study.

Offidani M, Corvatta L, Marconi M, Visani G, Alesiani F, Brunori M, Galieni P, Catarini M, Burattini M, Centurioni R, Rupoli S, Scortechini AR, Giuliodori L, Candela M, Capelli D, Montanari M, Olivieri A, Piersantelli MN, Leoni P.

Haematologica. 2006 Jan;91(1):133-6.

30.

Fludarabine combination regimen severely affected peripheral blood stem cell mobilization.

Laszlo D, Galieni P, Raspadori D, Tozzi M, Lauria F, Martinelli G.

Acta Haematol. 2004;111(4):228-9. No abstract available.

PMID:
15153717
31.

Typical genomic imbalances in primary MALT lymphoma of the orbit.

Matteucci C, Galieni P, Leoncini L, Lazzi S, Lauria F, Polito E, Martelli MF, Mecucci C.

J Pathol. 2003 Aug;200(5):656-60.

PMID:
12898603
32.

Immunoglobulin gene rearrangement analysis in composite hodgkin disease and large B-cell lymphoma: evidence for receptor revision of immunoglobulin heavy chain variable region genes in Hodgkin-Reed-Sternberg cells?

Bellan C, Lazzi S, Zazzi M, Lalinga AV, Palummo N, Galieni P, Marafioti T, Tonini T, Cinti C, Leoncini L, Pileri SA, Tosi P.

Diagn Mol Pathol. 2002 Mar;11(1):2-8.

PMID:
11854595
33.

Long-term follow-up of human herpes virus 6 infection in autologous bone marrow transplant recipients.

Galieni P, Moschettini D, Donati D, Tozzi M, Valensin PE, Lauria F.

Haematologica. 2001 Jul;86(7):782-3. No abstract available.

34.

Fludarabine containing-regimens may adversely affect peripheral blood stem cell collection in low-grade non Hodgkin lymphoma patients.

Laszlo D, Galieni P, Raspadori D, Scalia G, Bigazzi C, Bocchia M, Bucalossi A, Marotta G, Tozzi M, Lauria F.

Leuk Lymphoma. 2000 Mar;37(1-2):157-61.

PMID:
10721780
35.

Clinical outcome of extramedullary plasmacytoma.

Galieni P, Cavo M, Pulsoni A, Avvisati G, Bigazzi C, Neri S, Caliceti U, Benni M, Ronconi S, Lauria F.

Haematologica. 2000 Jan;85(1):47-51.

36.

Human herpesvirus 6 infection in autologous bone marrow transplant recipients: a prospective study.

Moschettini D, Galieni P, Valensin PE, Laszlo D, Scalia G, Tozzi M, Lauria F, Donati D.

J Med Virol. 2000 Jan;60(1):39-42.

PMID:
10568761
37.

Nongastrointestinal low-grade mucosa-associated lymphoid tissue lymphoma: analysis of 75 patients.

Zinzani PL, Magagnoli M, Galieni P, Martelli M, Poletti V, Zaja F, Molica S, Zaccaria A, Cantonetti AM, Gentilini P, Guardigni L, Gherlinzoni F, Ribersani M, Bendandi M, Albertini P, Tura S.

J Clin Oncol. 1999 Apr;17(4):1254.

PMID:
10561186
38.

[Lymphomas presenting as Tietze's syndrome: a report of 4 clinical cases].

Cocco R, Galieni P, Bellan C, Fioravanti A.

Ann Ital Med Int. 1999 Apr-Jun;14(2):118-23. Review. Italian.

PMID:
10399374
39.

Behaviour of human lymphocytic isoenzymes of 5'-nucleotidase.

Rosi F, Agostinho AB, Carlucci F, Zanoni L, Porcelli B, Marinello E, Galieni P, Tabucchi A.

Life Sci. 1998;62(25):2257-66.

PMID:
9651114
40.

5'-nucleotidase activity in lymphocytes from patients affected by B-cell chronic lymphocytic leukemia.

Rosi F, Tabucchi A, Carlucci F, Galieni P, Lauria F, Zanoni L, Guerranti R, Marinello E, Pagani R.

Clin Biochem. 1998 Jun;31(4):269-72.

PMID:
9646951
41.

Isoenzymes of 5'-nucleotidase in human lymphocytes.

Marinello E, Tabucchi A, Carlucci F, Galieni P, Rosi F.

Adv Exp Med Biol. 1998;431:555-8. No abstract available.

PMID:
9598127
42.

Expression of the T-cell-specific tyrosine kinase Lck in normal B-1 cells and in chronic lymphocytic leukemia B cells.

Majolini MB, D'Elios MM, Galieni P, Boncristiano M, Lauria F, Del Prete G, Telford JL, Baldari CT.

Blood. 1998 May 1;91(9):3390-6.

43.

All-trans retinoic acid (ATRA) in patients with chronic myeloid leukemia in the chronic phase.

Russo D, Regazzi M, Sacchi S, Visani G, Lazzarino M, Avvisati G, Pelicci PG, Dastoli G, Grandi C, Iacona I, Candoni A, Grattoni R, Galieni P, Rupoli S, Liberati AM, Maiolo AT.

Leukemia. 1998 Apr;12(4):449-54.

PMID:
9557600
44.

CD4+/CD45RA+ 'naive' T cells and immunological response to influenza virus vaccine in B-cell chronic lymphocytic leukaemia patients.

Marotta G, Bucalossi A, Galieni P, Bigazzi C, Nuti S, Valenzin PE, Bocchia M, Lauria F.

Acta Haematol. 1998;99(1):18-21.

PMID:
9490560
45.

Recurrent septicemia in an immunocompromised patient due to probiotic strains of Bacillus subtilis.

Oggioni MR, Pozzi G, Valensin PE, Galieni P, Bigazzi C.

J Clin Microbiol. 1998 Jan;36(1):325-6. No abstract available.

46.

Localized orbital lymphoma.

Galieni P, Polito E, Leccisotti A, Marotta G, Lasi S, Bigazzi C, Bucalossi A, Frezza G, Lauria F.

Haematologica. 1997 Jul-Aug;82(4):436-9.

47.

Uncoupling of T-cell antigen receptor and downstream protein tyrosine kinases in common variable immunodeficiency.

Majolini MB, D'Elios MM, Boncristiano M, Galieni P, Del Prete G, Telford JL, Baldari CT.

Clin Immunol Immunopathol. 1997 Jul;84(1):98-102.

PMID:
9191889
48.

2-Chlorodeoxyadenosine in the treatment of relapsed/refractory chronic lymphoproliferative disorders.

Rondelli D, Lauria F, Zinzani PL, Raspadori D, Ventura MA, Galieni P, Birtolo S, Forconi F, Algeri R, Tura S.

Eur J Haematol. 1997 Jan;58(1):46-50.

PMID:
9020373
49.

Variant t(1;15;17)(q23;q22;q23) in a case of acute promyelocytic leukemia.

Galieni P, Marotta G, Vessichelli F, Diverio D, Minoletti F, Bucalossi A, Lo Coco F, Lauria F.

Leukemia. 1996 Oct;10(10):1658-61. No abstract available.

PMID:
8847903
50.

Clinical and radiological presentation of 95 orbital lymphoid tumors.

Polito E, Galieni P, Leccisotti A.

Graefes Arch Clin Exp Ophthalmol. 1996 Aug;234(8):504-9.

PMID:
8858356

Supplemental Content

Loading ...
Support Center